Diplomat Pharmacy (NYSE:DPLO) was downgraded by analysts at ValuEngine from a “buy” rating to a “hold” rating in a report released on Monday.
DPLO has been the topic of a number of other research reports. Zacks Investment Research downgraded Diplomat Pharmacy from a “hold” rating to a “sell” rating in a research report on Tuesday, May 1st. Barclays initiated coverage on Diplomat Pharmacy in a research report on Thursday, March 8th. They set an “overweight” rating and a $27.00 price target on the stock. Leerink Swann restated an “outperform” rating and set a $33.00 price target on shares of Diplomat Pharmacy in a research report on Friday, June 22nd. Finally, JPMorgan Chase & Co. upgraded Diplomat Pharmacy from a “neutral” rating to an “overweight” rating in a research report on Thursday, May 10th. Eight analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. Diplomat Pharmacy presently has an average rating of “Hold” and an average target price of $26.64.
Diplomat Pharmacy opened at $25.78 on Monday, according to MarketBeat Ratings. Diplomat Pharmacy has a twelve month low of $14.23 and a twelve month high of $28.74. The company has a current ratio of 0.88, a quick ratio of 0.57 and a debt-to-equity ratio of 0.59. The stock has a market cap of $1.90 billion, a price-to-earnings ratio of 29.17 and a beta of 1.33.
Diplomat Pharmacy (NYSE:DPLO) last released its quarterly earnings results on Monday, May 7th. The company reported $0.20 earnings per share for the quarter, missing the Zacks’ consensus estimate of $0.21 by ($0.01). Diplomat Pharmacy had a net margin of 0.23% and a return on equity of 8.80%. The firm had revenue of $1.34 billion for the quarter, compared to analysts’ expectations of $1.28 billion. During the same quarter in the previous year, the business earned $0.19 EPS. The company’s revenue for the quarter was up 24.4% on a year-over-year basis. analysts predict that Diplomat Pharmacy will post 0.92 EPS for the current fiscal year.
In other news, Director Jeffrey G. Park sold 13,875 shares of the firm’s stock in a transaction dated Wednesday, May 23rd. The stock was sold at an average price of $24.20, for a total transaction of $335,775.00. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, Director Shawn Tomasello sold 1,680 shares of the firm’s stock in a transaction dated Tuesday, June 5th. The stock was sold at an average price of $24.27, for a total value of $40,773.60. Following the completion of the sale, the director now directly owns 12,816 shares in the company, valued at $311,044.32. The disclosure for this sale can be found here. Insiders have sold 17,250 shares of company stock worth $419,364 over the last ninety days. Insiders own 24.70% of the company’s stock.
Several hedge funds and other institutional investors have recently bought and sold shares of DPLO. Point72 Asset Management L.P. grew its stake in shares of Diplomat Pharmacy by 1,424.3% in the first quarter. Point72 Asset Management L.P. now owns 939,562 shares of the company’s stock worth $18,932,000 after purchasing an additional 877,922 shares during the last quarter. Redwood Investments LLC bought a new stake in shares of Diplomat Pharmacy in the first quarter worth about $16,716,000. Matarin Capital Management LLC bought a new stake in shares of Diplomat Pharmacy in the first quarter worth about $12,790,000. Hood River Capital Management LLC bought a new stake in shares of Diplomat Pharmacy in the first quarter worth about $11,876,000. Finally, Phocas Financial Corp. grew its stake in shares of Diplomat Pharmacy by 142.9% in the fourth quarter. Phocas Financial Corp. now owns 663,187 shares of the company’s stock worth $13,310,000 after purchasing an additional 390,168 shares during the last quarter. 75.66% of the stock is currently owned by institutional investors.
Diplomat Pharmacy Company Profile
Diplomat Pharmacy, Inc operates as an independent specialty pharmacy in the United States. The company stocks, dispenses, and distributes prescriptions for various biotechnology and specialty pharmaceutical manufacturers. It also provides specialty infusion pharmacy, patient care coordination, clinical, compliance and persistency program, patient financial assistance, specialty pharmacy training/consulting, benefits investigation, prior authorization, risk evaluation and medication strategy, retail specialty, and hub services, as well as clinical and administrative support services to hospitals and health systems.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Diplomat Pharmacy Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Diplomat Pharmacy and related companies with MarketBeat.com's FREE daily email newsletter.